Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRG | P48443 | 5/20 | 0.39 |
| ▸ | RXRA | P19793 | 4/20 | 0.39 |
| ▸ | RXRB | P28702 | 4/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13943179 | 0.95 | RXRG (0.39) | RXRGRXRARXRBDRD4NISCH | |
| SCHEMBL5751415 | 0.87 | HTR2A (0.39) | ACHEHTR2ASLC6A4CYP1A2CYP2D6 | |
| SCHEMBL30977517 | 0.87 | HTR2A (0.39) | ACHEHTR2ASLC6A4CYP1A2CYP2D6 | |
| SCHEMBL5029748 | 0.84 | DRD4 (0.42) | RXRGRXRARXRBDRD4NISCH | |
| SCHEMBL31598395 | 0.84 | DRD4 (0.42) | RXRGRXRARXRBDRD4NISCH | |
| SCHEMBL29851805 | 0.78 | RXRA (0.39) | RXRGRXRARXRBDRD4NISCH | |
| SCHEMBL19322587 | 0.78 | RXRA (0.39) | RXRGRXRARXRBDRD4NISCH | |
| SCHEMBL19684825 | 0.74 | HTR2C (0.41) | HTR2AADRA2A | |
| SCHEMBL14481407 | 0.74 | CYP1A2 (0.38) | RXRGRXRARXRBDRD4NISCH | |
| SCHEMBL8432407 | 0.73 | CYP1A2 (0.42) | HTR2ASLC6A4KDM4ECYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| WO-2019068772-A1 | NOVEL COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019034696-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034697-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| EP-2616460-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMA CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2013-10-03 | — | — | US | disclosed |
| WO-2013137479-A1 | DECAHYDROQUINOXALINE DERIVATIVES AND ANALOGS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-09-19 | — | — | WO | disclosed |
| WO-2012036253-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | RXRG 1373/4885RXRA 938/4885RXRB 1333/4885 |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | RXRG 2813/4885RXRA 2984/4885RXRB 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.